Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Allarity Therapeutics Inc (ALLR)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/10/2025: ALLR (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $5
1 Year Target Price $5
| 0 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -45.92% | Avg. Invested days 10 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 07/10/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 15.83M USD | Price to earnings Ratio - | 1Y Target Price 5 |
Price to earnings Ratio - | 1Y Target Price 5 | ||
Volume (30-day avg) 1 | Beta -0.15 | 52 Weeks Range 0.61 - 7.45 | Updated Date 07/10/2025 |
52 Weeks Range 0.61 - 7.45 | Updated Date 07/10/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 648.26 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -48.96% | Return on Equity (TTM) -383.74% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -8004450 | Price to Sales(TTM) - |
Enterprise Value -8004450 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -0.08 | Shares Outstanding 15079600 | Shares Floating 15079572 |
Shares Outstanding 15079600 | Shares Floating 15079572 | ||
Percent Insiders 2.63 | Percent Institutions 0.61 |
Upturn AI SWOT
Allarity Therapeutics Inc
Company Overview
History and Background
Allarity Therapeutics, Inc., founded in 2004, is a clinical-stage pharmaceutical company focused on developing personalized cancer treatments. The company leverages its Drug Response Predictor (DRP) technology to identify patients most likely to respond to its cancer therapies.
Core Business Areas
- Drug Development: Focuses on developing and commercializing cancer therapies, utilizing the DRP technology to guide patient selection.
- DRP Technology: The DRP platform predicts patient response to specific cancer drugs, aiming to improve treatment outcomes and reduce unnecessary side effects.
Leadership and Structure
The leadership team consists of experienced pharmaceutical executives and scientists. The organizational structure is typical for a clinical-stage biotech company, emphasizing research and development.
Top Products and Market Share
Key Offerings
- stenosar: Stenosar is Allarityu2019s lead product candidate, being developed for the treatment of ovarian cancer, and is partnered with an EU company. The company believes it holds a meaningful market share in certain segments of the relapsed or refractory ovarian cancer market if approved. Competitors include major pharmaceutical companies with established ovarian cancer treatments.
- Ixabepilone DRPu00ae (DoceAllu00ae): Ixabepilone DRPu00ae (DoceAllu00ae) is a clinically validated DRP, that predicts which patients are most likely to respond to ixabepilone, a chemotherapeutic agent used in the treatment of metastatic breast cancer. DoceAllu00ae is partnered with a European company. Competitors are genetic testing companies like Foundation Medicine (FMI).
Market Dynamics
Industry Overview
The pharmaceutical industry, particularly the oncology segment, is highly competitive and rapidly evolving. Personalized medicine is gaining traction, with companies focusing on targeted therapies and diagnostics.
Positioning
Allarity Therapeutics aims to differentiate itself through its DRP technology, which it believes can improve treatment outcomes and reduce healthcare costs. Its competitive advantage lies in its ability to predict patient response to specific drugs.
Total Addressable Market (TAM)
The TAM for personalized cancer therapies is estimated to be in the billions of dollars. Allarity is positioned to capture a portion of this market by partnering and developing its DRP technology.
Upturn SWOT Analysis
Strengths
- Proprietary DRP technology
- Focus on personalized medicine
- Potential to improve treatment outcomes
- Partnerships with other companies
Weaknesses
- Limited financial resources
- Dependence on successful clinical trials
- Small market capitalization
- Significant debt load
Opportunities
- Expanding partnerships with pharmaceutical companies
- Developing new DRPs for other cancer drugs
- Increasing adoption of personalized medicine
- Potential for FDA approval of its lead product candidate
Threats
- Competition from larger pharmaceutical companies
- Failure of clinical trials
- Changes in regulatory landscape
- Difficulty in securing funding
Competitors and Market Share
Key Competitors
- FMI
Competitive Landscape
Allarity Therapeutics faces intense competition from larger, more established pharmaceutical and diagnostics companies. Its DRP technology could provide a competitive advantage if validated through clinical trials.
Growth Trajectory and Initiatives
Historical Growth: Allarity Therapeutics' growth has been dependent on the success of its clinical trials and partnerships. The company has experienced fluctuations in revenue and market capitalization.
Future Projections: Future growth is contingent upon regulatory approvals of its drug candidates and successful commercialization. Analyst estimates vary widely.
Recent Initiatives: Recent initiatives include focusing on advancing clinical trials for its lead product candidate stenosar, seeking partnerships to expand its product pipeline.
Summary
Allarity Therapeutics is a clinical-stage pharmaceutical company leveraging its DRP technology for personalized cancer treatments. It has potential, but faces stiff competition and financial constraints. Success hinges on clinical trial outcomes and partnerships. Significant debt load and small market capitalization present challenges. The company needs to continue advancing its clinical trials to stay competitive in a quickly evolving market.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Investment decisions should be made after consulting with a qualified financial advisor. Data may be subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Allarity Therapeutics Inc
Exchange NASDAQ | Headquaters Boston, MA, United States | ||
IPO Launch date 2021-12-21 | Founder, CEO & Director Mr. Thomas H. Jensen | ||
Sector Healthcare | Industry Biotechnology | Full time employees 6 | Website https://www.allarity.com |
Full time employees 6 | Website https://www.allarity.com | ||
Allarity Therapeutics, Inc., a clinical-stage precision medicine pharmaceutical company, focuses on developing novel anti-cancer therapeutics for patients with unmet medical needs. The company develops drugs for the personalized treatment of cancer using drug specific companion diagnostics generated by its proprietary drug response predictor technology. Its lead drug candidate includes Stenoparib, a novel dual inhibitor of poly-ADP-ribose polymerase (PARP1/2) that is being evaluated in a phase 2 clinical trial in patients with advanced and recurrent ovarian cancer. The company also develops stenoparib- DRP, a companion diagnostic product used in select patients for stenoparib treatment. Allarity Therapeutics, Inc. was incorporated in 2004 and is headquartered in Boston, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.